Coverage rules reviewed July 2026
To cover Wegovy for weight loss, most commercial plans require prior authorization documenting a BMI of 30 or higher (or 27+ with a weight-related condition such as high blood pressure or type 2 diabetes). Original Medicare and most Part D plans exclude it for weight loss by law, and many employer plans exclude weight-loss drugs entirely — so a denial is common and often appealable. Here is how each major payer handles Wegovy, and which appeal matches your denial.
What is specific to Wegovy
The 2024 cardiovascular indication is the most valuable coverage fact on this page. It is not tied to diabetes, so it can open Medicare Part D and weight-loss-excluding employer plans to a drug they would otherwise refuse.
Indications other than weight loss
This is the lever most people miss. Medicare cannot pay for a drug used for weight loss — the statutory exclusion is still in force — but it can pay for a separate FDA-approved indication. The same logic applies to an employer plan that excludes weight-loss drugs. So the question is rarely “is Wegovy covered” and usually “which approved indication do I actually have?”
- Cardiovascular event risk reduction — approved March 2024. Requires established cardiovascular disease plus obesity or overweight — notably NOT diabetes. This is the broadest non-weight coverage hook of any drug in the class.
- Noncirrhotic MASH with F2–F3 fibrosis (adults) — approved August 2025. Accelerated approval, contingent on a confirmatory trial.
Medicare GLP-1 Bridge — includes Wegovy
Included — both the injection and the Wegovy tablet. Under the Bridge you pay $50 flat per one-month supply, whatever the drug or dose, from July 1, 2026 – December 31, 2027.
Type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease disqualify you — those conditions are already covered Part D indications, so the Bridge sends you there instead.
- The $50 does not count toward your deductible or out-of-pocket cap, and Extra Help does not reduce it.
- There is no appeals process — a denied prior authorization can only be resubmitted.
- It is a time-limited demonstration, not a change in the law. Medicare still excludes weight-loss drugs by statute.
- Plans do not opt in. CMS runs it outside the Part D benefit through a central processor.
- 3.8 million Medicare beneficiaries would have met the criteria in 2023 — about 8% of Part D enrollees (KFF, June 2026).
Full detail on the program: the Medicare GLP-1 Bridge explained.
The criterion payers apply to Wegovy and not its siblings
The MASH pathway is not a formality: Cigna requires documented stage F2 or F3 fibrosis before starting, a prescriber who is an endocrinologist, gastroenterologist or hepatologist, and an alcohol-intake limit. No sibling drug carries any of those.
Source: Cigna, Weight Loss – GLP-1 Agonists PA policy. Criteria are the named payer's published policy and vary by plan and year.
How major insurers typically cover Wegovy
Coverage varies by your specific plan (two people with the same insurer can have different benefits), changes every year, and depends on your diagnosis. Use this as a starting point, then confirm with your plan’s current formulary.
| Insurer | Typical Wegovy coverage | Full policy |
|---|---|---|
| Aetna | Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs | Aetna GLP-1 policy → |
| Blue Cross Blue Shield | Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs | Blue Cross Blue Shield GLP-1 policy → |
| UnitedHealthcare | Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs | UnitedHealthcare GLP-1 policy → |
| Cigna | Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs | Cigna GLP-1 policy → |
| Kaiser Permanente | Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs | Kaiser Permanente GLP-1 policy → |
| Medicare (Part D) | Excluded for weight loss by law; may cover for a separate FDA indication (e.g. CV risk, OSA) | Medicare (Part D) GLP-1 policy → |
| Medicaid | State-dependent — only about a dozen states cover weight-loss GLP-1s (down from a 2025 peak) | Medicaid GLP-1 policy → |
Prior authorization is the norm for GLP-1s. “Covered” almost always means “covered if your plan approves a prior-authorization request.” Verify every detail against your plan’s current formulary.
How to check your Wegovy coverage
- Call the member-services number on the back of your insurance card and ask if Wegovy is on your formulary, on which tier, and what the prior-authorization criteria are.
- Search your plan’s online drug list (formulary) for Wegovy and any step-therapy or quantity limits.
- Ask your prescriber to submit a prior-authorization request with your diagnosis and supporting documentation.
- Confirm whether your plan is fully-insured or a self-funded employer (ASO) plan — employer plans often set their own GLP-1 exclusions regardless of the insurer’s logo.
If your Wegovy claim is denied
Denials are common and often reversible. Request the written denial and the cited policy, then file an internal appeal with a letter of medical necessity; you can escalate to an independent external review. Our insurance appeal letter generator builds a starting draft. If coverage truly isn’t available, compare the cheapest cash-pay routes on the Wegovy without insurance and Wegovy cost guides.
Does my insurance cover Wegovy?
Does Aetna cover Wegovy?
Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs. If a plan refuses on the weight-loss benefit, the indication to ask about for Wegovy is cardiovascular event risk reduction. Coverage is set by your specific plan and changes yearly, so confirm with Aetna using the number on your card. See our full Aetna GLP-1 coverage guide for prior-authorization criteria and appeal steps.
Does Blue Cross Blue Shield cover Wegovy?
Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs. If a plan refuses on the weight-loss benefit, the indication to ask about for Wegovy is cardiovascular event risk reduction. Coverage is set by your specific plan and changes yearly, so confirm with Blue Cross Blue Shield using the number on your card. See our full Blue Cross Blue Shield GLP-1 coverage guide for prior-authorization criteria and appeal steps.
Does UnitedHealthcare cover Wegovy?
Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs. If a plan refuses on the weight-loss benefit, the indication to ask about for Wegovy is cardiovascular event risk reduction. Coverage is set by your specific plan and changes yearly, so confirm with UnitedHealthcare using the number on your card. See our full UnitedHealthcare GLP-1 coverage guide for prior-authorization criteria and appeal steps.
Does Cigna cover Wegovy?
Varies by employer plan — prior auth + BMI; many plans exclude weight-loss drugs. If a plan refuses on the weight-loss benefit, the indication to ask about for Wegovy is cardiovascular event risk reduction. Coverage is set by your specific plan and changes yearly, so confirm with Cigna using the number on your card. See our full Cigna GLP-1 coverage guide for prior-authorization criteria and appeal steps.
Does Medicare (Part D) cover Wegovy?
Excluded for weight loss by law; may cover for a separate FDA indication (e.g. CV risk, OSA). Since July 2026 there is a second route: the Medicare GLP-1 Bridge covers Wegovy at $50 flat per one-month supply, whatever the drug or dose for members who qualify, outside the Part D benefit. Included — both the injection and the Wegovy tablet. Coverage is set by your specific plan and changes yearly, so confirm with Medicare (Part D) using the number on your card. See our full Medicare (Part D) GLP-1 coverage guide for prior-authorization criteria and appeal steps.
Does Medicaid cover Wegovy?
State-dependent — only about a dozen states cover weight-loss GLP-1s (down from a 2025 peak). If a plan refuses on the weight-loss benefit, the indication to ask about for Wegovy is cardiovascular event risk reduction. Coverage is set by your specific plan and changes yearly, so confirm with Medicaid using the number on your card. See our full Medicaid GLP-1 coverage guide for prior-authorization criteria and appeal steps.
Wegovy denied by insurance: which denial did you get?
“Denied” is four different outcomes wearing the same word, and they are not appealed the same way — one of them is barely worth appealing at all. Your denial letter says which you got; the plan is required to tell you the basis in writing. Find yours below before you spend a week on the wrong fight.
Prior authorization was never submitted, or came back incomplete
How you know it's this one: The letter says "no prior authorization on file" or lists missing documentation.
What actually moves it: This is the most common denial and the least serious: nothing about your eligibility was judged. The prescriber's office submits the PA form with the diagnosis, the clinical justification, and any labs the plan asked for. Ask them to confirm it was actually filed, and to send you the plan's PA criteria for Wegovy so you can see what has to be in it.
Step therapy — the plan wants you to fail something cheaper first
How you know it's this one: The letter names another drug you must try, or says "step therapy requirement not met".
What actually moves it: You can ask for a step-therapy exception. The grounds are clinical, not financial: you have already tried the required drug, or it is contraindicated for you, or it is expected to be ineffective given your history. Your prescriber has to make that case in writing — a patient asking on their own rarely moves it. Pennsylvania Medicaid requires either a completed titration to semaglutide 2 mg or documented failure of max-dose Ozempic before it approves Wegovy 2.4 mg. The step above Wegovy is usually its own molecule at a lower dose, not a different drug.
The plan excludes weight-loss drugs entirely
How you know it's this one: The letter says the benefit is "not covered under your plan" rather than not medically necessary.
What actually moves it: This one is not a medical decision and an appeal usually will not move it — the employer bought a plan without the benefit. It is worth asking HR whether the exclusion has an exception process. The other route is a different diagnosis: Wegovy is the one drug here with a real answer. Its 2024 cardiovascular indication is not tied to diabetes, so with established cardiovascular disease plus obesity or overweight the claim can go in under that indication instead — a weight-loss benefit exclusion does not reach it. The MASH indication works the same way with documented F2–F3 fibrosis. Where neither applies, cash-pay is the realistic answer and pretending otherwise wastes your time.
The diagnosis or criteria on file do not meet the plan’s threshold
How you know it's this one: The letter cites BMI, A1c, or a comorbidity requirement you did not meet on paper.
What actually moves it: Often the clinical facts qualify but the paperwork did not carry them. Ask the plan, in writing, for the exact criteria it applied and the records it reviewed. If a qualifying comorbidity or a documented weight history was not in the file, that is what the appeal supplies.
How to get Wegovy covered by insurance
The mechanics — what to gather, how the appeal ladder works for your payer type, the exact Medicare Part D deadlines, and the distinction between a criteria denial you can win and a benefit exclusion you cannot — are the same for every GLP-1, so they live in one place rather than being restated on each drug page: GLP-1 insurance coverage.
The two steps worth repeating here, because they decide the rest: get the denial in writing with the criteria the plan applied (you are entitled to it, and you cannot appeal what you cannot read), and match the appeal to the denial type above — an appeal arguing medical necessity against a flat plan exclusion loses however well written. Your prescriber writes it; plans respond to clinical documentation from the prescribing office, and a patient letter is a supplement rather than the case. Appeal-letter generator.
GLP1Zoom is not an insurer, a pharmacy, or your prescriber, and none of this is legal or medical advice. Appeal rights and deadlines are set by your plan and by state and federal law — read your denial letter for yours, and confirm anything here with your plan and your clinician.
Editorial summary of how payers generally handle Wegovy — not a guarantee of coverage or medical/insurance advice. Always verify with your plan. Compare all insurer GLP-1 policies · Full disclaimer.